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Oncogenic Kras is increasingly appreciated as an instigator of an inflammatory program that facilitates
pancreatic cancer. In this issue of Cancer Cell, McAllister and colleagues use both gain-of-function and
loss-of-function studies to demonstrate that oncogenic Kras activates an IL-17-dependent pathway that
promotes the initiation and progression of preinvasive pancreatic neoplasia.Pancreatic cancer is well known for its
very poor prognosis. The disease is noto-
riously refractory to standard therapy,
especially for patients who present with
metastatic disease. Unfortunately, the
‘‘statistics’’ are getting worse. Pancreatic
cancer is one of only two cancers among
21 histotypes for which the death rate in
the United States rose from 1990 to
2008 (the other is liver/intrahepatic bile
duct cancer). Pancreatic cancer is likely
to become the second leading cause of
cancer-related death in the United States
by 2020 (behind lung cancer, which is
declining). Although new combination
chemotherapies are able to stabilize
many patients who present with meta-
static pancreatic cancer (representing
a major clinical advance), response rates
remain <35%, and patients with long-
term complete remissions after treatment
with these therapies are rare.
In the context of this unmet clinical
need, genetically engineered murine
models of pancreatic neoplasia have
become an increasingly important tool to
garner biological insights that might lead
to novel therapeutic strategies. Based
largely on the selective expression of
oncogenic Kras in the pancreas of
immune-competent hosts, these models
reproduce key biological aspects of the
human disease, including its highly des-
moplastic and inflammatory tumor micro-
environment. These models offer the
opportunity to uncover novel ‘‘non-tumor
cell autonomous’’ therapeutic targets in
the tumor stroma, which can be tested
for efficacy in tumor-bearing mice prior
to translation to the clinic (Beatty et al.,
2011). Because pathology in thesemodels advances from preinvasive dis-
ease to invasive disease, agents that pre-
vent or reverse the earliest neoplastic
events can also be explored.
In this issue of Cancer Cell, McAllister
et al. (2014) identify early inflammatory
events, dependent on the cytokine inter-
leukin-17 (IL-17) and oncogenic Kras,
that drive pancreatic neoplasia in vivo in
the Mist1CreERT2/+; LSL-KrasG12D murine
genetic model. IL-17 and related cyto-
kines potently evoke tissue inflammation
and can trigger autoimmunity by interact-
ing with multiple cell types in various
tissues. In cancer, the role of IL-17 (as
well as that of Th17 cells, helper T cells
that secrete IL-17) is far from clear cut;
in some experimental systems, Th17 cells
promote tumor formation, but, in other
studies, Th17 cells have clear, direct,
and powerful antitumor effects (Chen
and Oppenheim, 2014). In addition, IL-17
has been shown to mediate a paracrine
network that promotes tumor resistance
to antiangiogenic therapy by the induction
of GCSF expression and recruitment of
immunosuppressive immature myeloid
cells in the tumor microenvironment
(Chung et al., 2013). Many of these
studies, however, focus on implantable
tumor models or employ immune-incom-
petent mice, for which the tumor microen-
vironment, especially at early stages of
neoplastic growth, is not ideally repro-
duced. In their genetic model, McAllister
et al. (2014) identify two distinct IL-17-
secreting lymphoid cell populations,
Th17 cells and gdT cells, recruited to the
pancreas in the setting of mutant
Kras expression and inflammation. Both
cellular subsets are rare in the tissue,Cancer Celoutnumbered by myeloid inflammatory
cells, and, in fact, were not specifically
noted in the initial immunophenotyping
studies of genetically engineered mice
bearing Kras-driven pancreatic intraepi-
thelial neoplastic (PanIN) lesions (Clark
et al., 2007). Nevertheless, in both gain-
of-function and loss-of-function studies
in vivo, McAllister et al. (2014) demon-
strate that IL-17 helps to drive initiation
and progression of pancreatic neoplasia.
Interestingly, Th17 cells have been previ-
ously reported to promote pancreatic
inflammation in the setting of autoimmune
diabetes in immune-incompetent mice in
which anti-IL-17 treatment reduces insu-
litic inflammation and disease progres-
sion (Martin-Orozco et al., 2009). In
human PanIN tissues, McAllister et al.
(2014) identify many elements of the
IL-17 inflammatory fingerprint, including
PanIN-infiltrating lymphocytes that ex-
press RORgt, the transcription factor
classically linked to Th17 cells. These
findings underscore the potential rele-
vance of IL-17 in the initiation of human
pancreatic cancer.
McAllister et al. (2014) also observe
Kras-dependent expression of functional
IL-17 receptor (IL-17R) on pancreatic
neoplastic epithelium. Based on a genetic
lineage tracing allele, IL-17R expression is
also evident on pancreatic neoplastic
cells undergoing epithelial-mesenchymal
transition. Neutralization of IL-17 in vivo
leads to a rapid change in the gene
expression program of neoplasic cells,
including the loss of IL-6 expression and
STAT-3 phosphorylation, two key regula-
tors of pancreatic neoplastic progression
(McAllister et al., 2014). Importantly, thisl 25, May 12, 2014 ª2014 Elsevier Inc. 553
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only in the presence of oncogenic Kras.
Although it remains to be determined if
IL-17R signaling triggers a cell-intrinsic
effect that promotes oncogenesis, there
likely is a paracrine aspect of IL-17 in
the neoplastic microenvironment, culmi-
nating in a disease-promoting scenario.
The findings are significant for a num-
ber of reasons. First, these results under-
score a role for IL-17 as an inflammatory
mediator that promotes neoplasia. Sec-
ond, the results offer novel insights
regarding the role of IL-17 in pancreatic
neoplasia in particular and Kras-mediated
oncogenesis in general. Third, the find-
ings point to a potential translational
path to neutralize IL-17 in patients with
pancreatic neoplasia, or those at high
risk, given the active development of
effective IL-17 monoclonal antibodies
that have shown stunning promise in
other (noncancer) inflammatory diseases
(van den Berg and McInnes, 2013).
Curiously, CD4 T cell depletion in this
model (by the use of depleting mono-
clonal antibody) reproduces aspects of
the phenotype observed with IL-17
neutralization, even though only a small
fraction of CD4 T cells secrete IL-17 and
other IL-17-secreting cells identified
(such as gd T cells) do not express CD4.
These observations are consistent with a
second report published earlier this year
that IL-17 secreting CD4 T cells are found
in the pancreas upon induction of mutant
Kras and treatment with the inflammatory
agent cerulein and that genetic deletion of
CD4 cells abrogates PanIN formation, an
effect that requires CD8 T cells (Zhang
et al., 2014). Regulatory T cells (Tregs)
comprise a far larger percentage of
PanIN-infiltrating CD4 T cells than Th17554 Cancer Cell 25, May 12, 2014 ª2014 Elscells, and, therefore, Th17 cells, Tregs,
and perhaps CD4 Th2 T cells may coop-
erate to accelerate pancreatic neoplasia
disease. Accumulating evidence shows
that Th17 cells and Tregs can stimulate
each other in vivo such that therapeutic
manipulation of one cell type will impact
the other (Chen and Oppenheim, 2014).
Further experiments are needed to
evaluate whether IL-17 neutralization is
as useful a therapeutic strategy in the
setting of invasive pancreatic carcinoma
as it appears to be, at least experimen-
tally, in the early stages of pancreatic
neoplasia. The development of potent,
clinical-grade anti-IL-17 mAb certainly
presents a translational temptation (van
den Berg and McInnes, 2013); however,
additional studies are needed to ensure
that such treatment would not be counter-
productive, given the antitumor activity
of Th17 in certain models (Chen and Op-
penheim, 2014). Such strategies are
amenable for testing via genetically engi-
neered mice with pancreatic cancer.
Finally, it is of great interest that the IL-
17 phenotype reported byMcAllister et al.
(2014) emerges in the setting of onco-
genic Kras, which appears capable of
orchestrating a tumor-promoting micro-
environment beyond well-described
tumor-cell autonomous Kras mecha-
nisms. GMCSF expression by PanIN and
invasive pancreatic cancer cells is
another example of a pathway down-
stream from oncogenic Kras that has
non-cell autonomous effects, in this case
functioning to establish an influx of
suppressive myeloid cells that inhibit
adaptive immunity (Bayne et al., 2012;
Pylayeva-Gupta et al., 2012). Pharmaco-
logical inhibition of oncogenic Kras, there-
fore, might realistically be expected toevier Inc.derail these tumor-promoting non-cell
autonomous mechanisms, providing
even more incentive (if more were
needed) for renewed efforts to drug Kras.ACKNOWLEDGMENTS
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